SA523440043B1 - أجسام مضادة ضد cd3 إبسيلون جديدة - Google Patents
أجسام مضادة ضد cd3 إبسيلون جديدةInfo
- Publication number
- SA523440043B1 SA523440043B1 SA523440043A SA523440043A SA523440043B1 SA 523440043 B1 SA523440043 B1 SA 523440043B1 SA 523440043 A SA523440043 A SA 523440043A SA 523440043 A SA523440043 A SA 523440043A SA 523440043 B1 SA523440043 B1 SA 523440043B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- new anti
- complement
- specific region
- antibodies
- set consisting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017102622 | 2017-09-21 | ||
| PCT/CN2018/106618 WO2019057099A1 (en) | 2017-09-21 | 2018-09-20 | NOVEL ANTI-CD3EPSILON ANTIBODIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA523440043B1 true SA523440043B1 (ar) | 2024-02-08 |
Family
ID=65811028
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA523440043A SA523440043B1 (ar) | 2017-09-21 | 2020-03-19 | أجسام مضادة ضد cd3 إبسيلون جديدة |
| SA520411577A SA520411577B1 (ar) | 2017-09-21 | 2020-03-19 | أجسام مضادة ضد cd3 إبسيلون جديدة |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA520411577A SA520411577B1 (ar) | 2017-09-21 | 2020-03-19 | أجسام مضادة ضد cd3 إبسيلون جديدة |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11440962B2 (enExample) |
| EP (1) | EP3684806A4 (enExample) |
| JP (2) | JP7305624B2 (enExample) |
| KR (2) | KR102785140B1 (enExample) |
| CN (2) | CN111108119B (enExample) |
| AU (2) | AU2018336519B2 (enExample) |
| BR (1) | BR112020004992A2 (enExample) |
| CA (1) | CA3074130A1 (enExample) |
| EA (1) | EA202090800A1 (enExample) |
| IL (1) | IL273393A (enExample) |
| MX (1) | MX2020003087A (enExample) |
| MY (1) | MY199530A (enExample) |
| PH (1) | PH12020550078A1 (enExample) |
| SA (2) | SA523440043B1 (enExample) |
| SG (1) | SG11202001358RA (enExample) |
| TW (2) | TWI820041B (enExample) |
| WO (1) | WO2019057099A1 (enExample) |
| ZA (1) | ZA202001314B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL273424B2 (en) | 2017-09-22 | 2024-09-01 | Wuxi Biologics Ireland Ltd | Novel bispecific cd3/cd19 polypeptide complexes |
| IL273217B2 (en) | 2017-09-22 | 2025-04-01 | Wuxi Biologics Ireland Ltd | Novel bispecific polypeptide complexes |
| EP3973000A4 (en) * | 2019-06-07 | 2023-09-06 | Adimab, LLC | HIGH AFFINITY ANTI-CD3 ANTIBODIES AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| US20230067182A1 (en) * | 2019-11-29 | 2023-03-02 | Boe Technology Group Co., Ltd. | Data Processing Device and Method, and Computer Readable Storage Medium |
| JP7765397B2 (ja) | 2020-03-12 | 2025-11-06 | イミューン－オーエヌシー セラピューティクス，インコーポレーテッド | 新規抗ｌｉｌｒｂ４抗体および派生産物 |
| JP2023528350A (ja) | 2020-05-27 | 2023-07-04 | ヤンセン バイオテツク，インコーポレーテツド | Ｃｄ３抗原結合ドメインを含むタンパク質及びその使用 |
| WO2022022464A1 (zh) * | 2020-07-27 | 2022-02-03 | 正大天晴药业集团股份有限公司 | 新型双特异性抗cd3/cd20多肽复合物配制剂 |
| US11795224B2 (en) * | 2021-03-24 | 2023-10-24 | China Medical University Hospital | Anti-T-cell nanobody and nucleic acid encoding sequence thereof, and uses of the same |
| US12258406B2 (en) | 2021-03-24 | 2025-03-25 | Twist Bioscience Corporation | Antibodies that bind CD3 Epsilon |
| CN115536740A (zh) * | 2021-06-30 | 2022-12-30 | 苏州方德门达新药开发有限公司 | 介导细胞内有效滞留cd3的空间构象表位及其应用 |
| CN115558023A (zh) * | 2021-07-02 | 2023-01-03 | 安源医药科技（上海）有限公司 | 抗cd3抗体及其用途 |
| CN118922442A (zh) * | 2022-03-14 | 2024-11-08 | 成都盛世君联生物技术有限公司 | 一种抗cd3抗体及其制备方法和用途 |
| CN115286715B (zh) * | 2022-05-18 | 2023-05-23 | 上海百英生物科技股份有限公司 | 一种抗cd3的纳米抗体或其抗原结合部分及其制备方法 |
| AU2023367039A1 (en) * | 2022-10-25 | 2025-05-15 | Ablexis, Llc | Anti-cd3 antibodies |
| EP4623007A1 (en) | 2022-11-24 | 2025-10-01 | WuXi Biologics Ireland Limited | Psma antibodies and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020142000A1 (en) * | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| CN1169953C (zh) * | 1999-11-30 | 2004-10-06 | 中国医学科学院中国协和医科大学血液学研究所血液病医院 | 抗cd3单克隆抗体重链和轻链可变区基因及其应用 |
| UA94211C2 (ru) * | 2004-06-03 | 2011-04-26 | Новиммюн С.А. | Выделенное полностью человеческое моноклональное cd3 антитело |
| DK1940881T3 (en) * | 2005-10-11 | 2017-02-20 | Amgen Res Munich Gmbh | COMPOSITIONS WITH ARTICLE CROSS-SPECIFIC ANTIBODIES AND APPLICATIONS THEREOF |
| CA2682626A1 (en) * | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
| FI2155783T4 (fi) * | 2007-04-03 | 2022-12-15 | Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni | |
| WO2010037836A2 (en) | 2008-10-01 | 2010-04-08 | Micromet Ag | Cross-species-specific psmaxcd3 bispecific single chain antibody |
| WO2011109588A1 (en) | 2010-03-03 | 2011-09-09 | Health Research Inc. | Novel cd3 epsilon immunogens and antibodies |
| CN104098698B (zh) * | 2013-04-08 | 2019-04-05 | 中国人民解放军第二军医大学 | 一种抗cd3抗体及其制法和应用 |
| SG11201509361TA (en) * | 2013-05-28 | 2015-12-30 | Numab Ag | Novel antibodies |
| CN112390883A (zh) | 2013-12-17 | 2021-02-23 | 基因泰克公司 | 抗cd3抗体及使用方法 |
| AU2015266077A1 (en) | 2014-05-28 | 2016-09-29 | F. Hoffmann-La Roche Ag | Antibodies binding to human and cynomolgus CD3 epsilon |
| AU2015329965A1 (en) * | 2014-10-09 | 2017-04-27 | Engmab Sàrl | Bispecific antibodies against CD3epsilon and ROR1 |
| TN2018000324A1 (en) * | 2015-01-23 | 2020-01-16 | Sanofi Sa | ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123 |
-
2018
- 2018-09-20 KR KR1020207011016A patent/KR102785140B1/ko active Active
- 2018-09-20 CN CN201880056557.3A patent/CN111108119B/zh active Active
- 2018-09-20 CN CN202211326811.1A patent/CN115991777A/zh active Pending
- 2018-09-20 AU AU2018336519A patent/AU2018336519B2/en active Active
- 2018-09-20 SG SG11202001358RA patent/SG11202001358RA/en unknown
- 2018-09-20 US US16/649,149 patent/US11440962B2/en active Active
- 2018-09-20 BR BR112020004992-1A patent/BR112020004992A2/pt unknown
- 2018-09-20 KR KR1020257008876A patent/KR20250046337A/ko active Pending
- 2018-09-20 EA EA202090800A patent/EA202090800A1/ru unknown
- 2018-09-20 TW TW107133192A patent/TWI820041B/zh active
- 2018-09-20 MX MX2020003087A patent/MX2020003087A/es unknown
- 2018-09-20 WO PCT/CN2018/106618 patent/WO2019057099A1/en not_active Ceased
- 2018-09-20 JP JP2020516462A patent/JP7305624B2/ja active Active
- 2018-09-20 MY MYPI2020001058A patent/MY199530A/en unknown
- 2018-09-20 TW TW112146907A patent/TWI879275B/zh active
- 2018-09-20 EP EP18859373.5A patent/EP3684806A4/en active Pending
- 2018-09-20 CA CA3074130A patent/CA3074130A1/en active Pending
- 2018-09-20 PH PH1/2020/550078A patent/PH12020550078A1/en unknown
-
2020
- 2020-02-28 ZA ZA2020/01314A patent/ZA202001314B/en unknown
- 2020-03-18 IL IL273393A patent/IL273393A/en unknown
- 2020-03-19 SA SA523440043A patent/SA523440043B1/ar unknown
- 2020-03-19 SA SA520411577A patent/SA520411577B1/ar unknown
-
2022
- 2022-08-02 US US17/816,732 patent/US12485298B2/en active Active
-
2023
- 2023-06-28 JP JP2023105809A patent/JP7737193B2/ja active Active
-
2025
- 2025-02-28 AU AU2025201457A patent/AU2025201457A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA523440043B1 (ar) | أجسام مضادة ضد cd3 إبسيلون جديدة | |
| PH12020552010A1 (en) | Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof | |
| EA202092839A1 (ru) | Агенты, связывающиеся с psma, и виды их применения | |
| PH12021551487A1 (en) | Tumor-targeted agonistic cd28 antigen binding molecules | |
| UA120060C2 (uk) | Виділене біспецифічне антитіло до cd123 (il3-r-alpha)хcd3 і його застосування | |
| PH12021550361A1 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
| JOP20190236A1 (ar) | أجسام مضادة لـ ilt4 وشظايا ارتباط بمولد ضد | |
| MX2022002111A (es) | Novedosos anticuerpos anti-cldn18.2. | |
| NZ749840A (en) | Cd3 binding antibodies | |
| MX2022011002A (es) | Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos. | |
| ZA201905866B (en) | Anti-c5 antibodies and uses thereof | |
| AR105267A1 (es) | Anticuerpos de unión a tau | |
| CR20170383A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
| MX2021002710A (es) | Anticuerpos anti-c5 humanizados y usos de los mismos. | |
| NZ630610A (en) | Tau peptides, anti-tau antibodies, and methods of use thereof | |
| MX366359B (es) | Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1). | |
| PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof | |
| MX2022007961A (es) | Nuevos anticuerpos anti-fgfr2b. | |
| UY37683A (es) | Anticuerpo monoclonal anti-pd-l1 monoclonal | |
| CO2017004753A2 (es) | Anticuerpos que se unen a ccr6 | |
| MX2020003093A (es) | Anticuerpos anti-cd19 novedosos. | |
| MX2022007960A (es) | Nuevos anticuerpos anti-fgfr2b. | |
| MX2020010092A (es) | Variantes de anticuerpo c-terminales. | |
| MX2020004026A (es) | Anticuerpo monoclonal anti-il-5ra. | |
| CL2021001104A1 (es) | Anticuerpo monoclonal que se une específicamente al antígeno cd20 |